Could fewer infusions be enough for thyroid eye disease?
NCT ID NCT07308964
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) to the standard 8-infusion course in people with active thyroid eye disease. It aims to see if those who respond well early can safely stop treatment sooner. About 40 participants who show early improvement will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.